Abstract
Four clinical studies were conducted in over 30 countries with patients suffering from community-acquired pneumonia. Moxifloxacin (400 mg qd 10 d) was compared to clarithromycin (500 mg bid 10 d) or amoxicillin (1 g tid 10 d) all treatment was oral. Clinical results at first visit post therapy demonstrated 94.4% success among patients treated with moxifloxacin, compared with 92.9% among those who received clarithromycin or amoxicillin. Bacteriological response in the moxifloxacin group achieved 91%, which included 94% eradication of penicillin-resistant S. pneumoniae (MIC ≥1.0) (17/18 patients) and complete eradication of clarithromycin-resistant S. pneumoniae (MIC ≥8.0) (26/26 patients).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dalhoff A (1998) Moxifloxacin- Review of microbiology. Antipneumococcal activity. In: Programme and Abstracts of the 6th International Symposium on New Quinolones, Denver, p 56
Marchese A, Debbia EA, Schito GC (1998) Comparative activity of Bay 12–8039 and other fluoroquinolones on clinical Streptococcus pneumoniae strains. Poster at ECC Hamburg
Lister PD, Sanders CC (1998) Pharmacodynamics of moxifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Poster at ICAAC San Diego, Abstract No. A21
Dalhoff A (1998) Moxifloxacin-review of microbiology. Activity against H. influenzae and H. parainfluenzae. In: Programme and Abstracts of the 6th International Symposium on New Quinolones, Denver
Focht J (1998) In vitro activity of Bay 12-8039 compared with other fluoroquinolones against bacterial strains from upper and lower respiratory tract infections in general practice. Poster ICID Boston 1998
Wise R, Andrews JM, Brenwald N (1996) In vitro activity of a new 8-methoxyquinolone Bay 12-8039 in comparison with other fluoroquinolones and B-lactams against recent isolates of Chlamydia. Poster at ICAAC New Orleans
Andrews J, Honeybourne D, Jevons G, Wise R (1998) Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single, 400 mg oral dose. Poster at IAAC San Diego, Abstract No. A29
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Springsklee, M. (2000). Clinical Needs in The Millennium — Pneumonia — The Role of Moxifloxacin. In: Mandell, L. (eds) First International Moxifloxacin Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59681-0_28
Download citation
DOI: https://doi.org/10.1007/978-3-642-59681-0_28
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64081-0
Online ISBN: 978-3-642-59681-0
eBook Packages: Springer Book Archive